- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.05. | Syra Health Wins $5.8 Mln Indiana Contract To Lead Child Mental Health Access Site | 1 | RTTNews | ||
| 20.05. | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Syra Health embarks on search for new CEO | 1 | Investing.com | ||
| 20.05. | Syra Health beginnt Suche nach neuem CEO | 2 | Investing.com Deutsch | ||
| 20.05. | Syra Health Board Begins CEO Search to Drive Growth | 64 | PR Newswire | CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB: SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering... ► Artikel lesen | |
| 09.05. | Syra Health GAAP EPS of -$0.04, revenue of $1.86M | 1 | Seeking Alpha | ||
| SYRA HEALTH Aktie jetzt für 0€ handeln | |||||
| 08.05. | Syra Health Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Syra Health Corp - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY | 60 | PR Newswire | Revenue increase led by Population Health's 261% YoY Expansion
Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY
Continued Efficiency Gains... ► Artikel lesen | |
| 08.04. | Syra Health Corp - 8-K, Current Report | 4 | SEC Filings | ||
| 01.04. | Syra Health to delist from Nasdaq Capital Market | 1 | Investing.com | ||
| 01.04. | Syra Health announces voluntary delisting from Nasdaq | 4 | Seeking Alpha | ||
| 01.04. | Syra Health kündigt Rückzug vom NASDAQ Capital Market an | 2 | Investing.com Deutsch | ||
| 01.04. | Syra Health Announces Voluntary Delisting from the Nasdaq Capital Market | 82 | PR Newswire | CARMEL, Ind., April 1, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering... ► Artikel lesen | |
| 13.03. | Syra Health sichert Vertragsverlängerung im Wert von 660.000 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.03. | Syra Health secures $660,000 population health contract extension | 1 | Seeking Alpha | ||
| 11.03. | Syra Health Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Syra Health Corp - 10-K, Annual Report | 1 | SEC Filings | ||
| 11.03. | Syra Health Announces Full-Year Revenue of $8.0 Million, Up 45% YoY | 215 | PR Newswire | 2024 Population Health Revenue Acceleration to 132% YoY
Q4 2024 Net Losses Cut Nearly in Half Compared to Q4 2023, Highlighting Major Efficiency Gains
Continued... ► Artikel lesen | |
| 11.03. | Syra Health GAAP EPS of -$0.50, revenue of $7.98M | 1 | Seeking Alpha |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,111 | 0,00 % | Original-Research: Sernova Biotherapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Sernova Biotherapeutics Inc - from First Berlin Equity Research GmbH 02.06.2025 / 13:39 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,800 | +8,40 % | Ascendiant Capital raises Atossa Genetics stock price target to $7.50 | ||
| PING AN HEALTHCARE | 0,755 | 0,00 % | PA GOODDOCTOR (01833): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | ||
| MOUNTAIN VALLEY MD | 0,012 | -16,44 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,274 | +3,01 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| VERU | 0,525 | -3,40 % | Veru Inc.: Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide ... | --Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial... ► Artikel lesen | |
| CYTOSORBENTS | 0,884 | -4,54 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 5,240 | -100,00 % | Tempest Therapeutics, Inc. - 8-K, Current Report | ||
| VOLITIONRX | 0,568 | -3,57 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
| EKSO BIONICS | 0,257 | 0,00 % | XFRA NEW INSTRUMENTS AVAILABLE ON 02.06.2025 | The following instruments on XETRA do have their first trading 02.06.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 02.06.2025
Aktien
1 LU0445408270 Altisource Portfolio... ► Artikel lesen | |
| IMUNON | 1,340 | +1,52 % | IMNN-001 shows promise in ovarian cancer treatment | ||
| BEYOND AIR | 0,158 | -1,86 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
| AVINGER | 0,340 | -6,08 % | Avinger Inc - 8-K, Current Report | ||
| NOVACYT | 0,552 | +0,36 % | Novacyt S.A. - Liquidity Agreement and Total Voting Rights | ||
| AROVELLA THERAPEUTICS | 0,039 | 0,00 % | XFRA E4NA: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen SYRA HEALTH CORP kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 0,105 Euro und damit +0,48 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYRA HEALTH CORP finden Sie auf Wallstreet Online.